Nuklearmedizin. Nuclear medicine最新文献_第7页

Dosimetry in a patient with peritoneal dialysis treated with [177Lu]Lu-PSMA-617. 用[177Lu]Lu-PSMA-617治疗一名腹膜透析患者的剂量测定。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2224-9536

Kathrin Glass, Andreas Hendrik Hering, Alexander Heinzel

引用次数: 0

Peculiar Pattern of Response Following [225Ac]Ac-PSMA Therapy: A Case Report with 'PSA Pseudoregression' Response Pattern. 225Ac]Ac-PSMA治疗后的奇特反应模式：PSA 伪回归 "反应模式的病例报告。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-05-17 DOI: 10.1055/a-2311-5679

Akram Al-Ibraheem, Feras Istatieh, A. Abdlkadir, Alaa’ Abufara, Baha’ Sharaf, R. Abu-Hijlih, NabeelaQublan Al-Hajaj, S. Salah

引用次数: 0

Computational Decision Support for PE Diagnosis based on Ventilation Perfusion Ratio. 基于通气灌注比的 PE 诊断计算决策支持。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-09 DOI: 10.1055/a-2287-2051

Julia Katharina Vogt, Wolfgang Kurt Vogt, Alexander Heinzel, F. Mottaghy

{"title":"Computational Decision Support for PE Diagnosis based on Ventilation Perfusion Ratio.","authors":"Julia Katharina Vogt, Wolfgang Kurt Vogt, Alexander Heinzel, F. Mottaghy","doi":"10.1055/a-2287-2051","DOIUrl":"https://doi.org/10.1055/a-2287-2051","url":null,"abstract":"AIM\u0000The aim of this study is to investigate whether computer-aided, semi-automated 3D lung lobe quantification can support decision-making on PE diagnosis based on the ventilation-perfusion ratio in clinical practice.\u0000\u0000\u0000METHODS\u0000A study cohort of 100 patients (39 male, 61 female, age 64.8±15.8 years) underwent ventilation/perfusion single photon emission computed tomography (V/Q-SPECT/CT) to exclude acute PE on SPECT/CT OPTIMA NM/CT 640 (GE Healthcare). Two 3D lung lobe quantification software tools (Q. Lung: Xeleris 4.0, GE Healthcare and LLQ: Hermes Hybrid 3D Lung Lobar Quantification, Hermes Medical Solutions) were used to evaluate the numerical lobar ventilation/perfusion ratio (VQR) and lobar volume/perfusion ratio (VPR). A test of linearity and equivalence of the two 3D software tools was performed using Pearson, Spearman, quadratic weighted kappa and the mean squared deviation for VPR/VQR. An algorithm was developed that identified PE candidates using ROC analysis. The agreement between the PE findings of an experienced nuclear medicine expert and the calculated PE candidates was represented by the magnitude of the YOUDEN index (J) and the size of the area under the receiver operating curve (AUC).\u0000\u0000\u0000RESULTS\u0000Both 3D software tools showed good comparability. The YOUDEN index for QLUNG(VPR/VQR)/LLQ(VPR/VQR) was in the range from 0.2 to 0.5. The mean AUC averaged over all lung lobes for QLUNG(VPR) was 0.66, CI95%: ±14.0%, for QLUNG(VQR) 0.66, CI95%: ±13.3%, for LLQ(VPR) 0.64, CI95%: ±14.7% and for LLQ(VQR) 0.65, CI95%: ±13.1%.\u0000\u0000\u0000CONCLUSION\u0000This study reveals that 3D software tools are feasible for numerical PE detection. The clinical decision can be supported by using a numerical algorithm based on ROC analysis.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL). FDG-PET/CT是预测和评估非霍奇金淋巴瘤（NHL）嵌合抗原受体（CAR）T细胞疗法反应的有力工具。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-09 DOI: 10.1055/a-2283-8417

C. Wielenberg, J. Fostitsch, Christian Volz, Reinhard Marks, K. Michalski, Ralph Wäsch, R. Zeiser, Juri Ruf, P. T. Meyer, Claudius Klein

{"title":"FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).","authors":"C. Wielenberg, J. Fostitsch, Christian Volz, Reinhard Marks, K. Michalski, Ralph Wäsch, R. Zeiser, Juri Ruf, P. T. Meyer, Claudius Klein","doi":"10.1055/a-2283-8417","DOIUrl":"https://doi.org/10.1055/a-2283-8417","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaining 15 (44.1%) patients had DS > 3 on PET-1. 14/19 patients with DS ≤ 3 on PET-1 had no relapsed or refractory (r/r)-disease and were still alive at last follow-up. The other 5 patients had r/r-disease and 4 of these died. Except for two patients who had no r/r-disease, all other patients (13/15) with DS > 3 on PET-1 had r/r-disease and 12 of these subsequently died. Patients with DS ≤ 3 on PET-1 had significantly better progression free survival (PFS; HR: 5.7; p < 0.01) and overall survival (OS; HR: 5.0; p < 0.01) compared to patients with DS > 3 on PET-1. In addition, we demonstrated that patients with DS ≤ 4 on PET-0 tended to have longer PFS (HR: 3.6; p = 0.05).Early FDG-PET/CT using the established DS after CAR T-cell therapy is a powerful tool to evaluate response to therapy.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients. 68Ga-PSMA PET/CT 对前列腺癌患者放射治疗计划的影响。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-05 DOI: 10.1055/a-2284-0593

Felix Bock, B. Frerker, Laura Schubert, Hannes Rennau, Jens Kurth, Bernd J. Krause, Guido Hildebrandt, S. Schwarzenböck

{"title":"Impact of 68Ga-PSMA PET/CT on radiation treatment planning of prostate cancer patients.","authors":"Felix Bock, B. Frerker, Laura Schubert, Hannes Rennau, Jens Kurth, Bernd J. Krause, Guido Hildebrandt, S. Schwarzenböck","doi":"10.1055/a-2284-0593","DOIUrl":"https://doi.org/10.1055/a-2284-0593","url":null,"abstract":"AIM\u0000This study aimed to assess the impact of 68Ga-PSMA PET/CT on radiation treatment (RT) planning in prostate cancer patients with salvage (sRT) or definitive (dRT) radiotherapy.\u0000\u0000\u0000METHODS\u000038 patients (27 sRT, median PSA 0.79 ng/ml (range 0.06-12.1); 11 dRT, median PSA 4.35 ng/ml (range 1.55-55.5) underwent 68Ga-PSMA PET/CT before RT. Influence of 68Ga-PSMA PET/CT on the extent of planning target volume (PTV) and addition of PET-based boosts were assessed. Median follow up was 12 months (range 3-24).\u0000\u0000\u0000RESULTS\u000068Ga-PSMA PET/CT showed positive findings in 23/38 patients (8/23: local recurrence (LR), 11/23: nodal metastasis, 1/23: LR and nodal, 2/23: solitary bone metastasis, 1/23: oligometastatic nodal/ bone metastases). In sRT primary PTV was changed in 16/27 patients extending the PTV to the lymphatic drainage (10/16), PSMA-positive LR (3/16), bone metastases (2/16) and both nodal/bone metastases (1/16). PET-based increase of primary PTV was 116%. PET-based boosts were administered in 19/27 patients (8/19: local, 10/19: nodal, 1/19: both), median boost volume was 31.3 cm3 (range 17.2-80.2) (local) and 19.7 cm3 (range 3.0-109.3) (nodal). PTV was changed in 1/11 (9%) of dRT patients (extension of primary PTV to the lymphatic drainage (RT volume of 644.5 cm3), additional nodal boost (volume of 2.7 cm3, 23.1 Gy)). All patients showed biochemical response (mean PSA decrease 88.8 +/- 14.0%). Nadir PSA was reached 10 months (range 1-17) after end of RT (median 0.07 ng/ml, range 0.002-3.96). Within a median 12 months follow-up (range 3-22/8-24 in sRT/dRT), median PSA was 0.05 ng/ml (range 0.002-8.5) (sRT) and 0.26 ng/ml (range 0.02-2.68) (dRT).\u0000\u0000\u0000CONCLUSIONS\u000068Ga-PSMA PET/CT influenced sRT planning in almost 63% and dRT in 9% of patients by change of PTV and additional boosts.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"2 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140739552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Exercise Echoes: Unusual Tc99m HDP Uptake in Thigh Adductors Post-Workout. 运动时的回声：运动后大腿内收肌对 Tc99m HDP 的异常摄取。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-05 DOI: 10.1055/a-2289-4301

Michael C.M. Gammel, K. Hansen, Wolfgang Weber, I. Rauscher

引用次数: 0

Intrapankreatische Nebenmilz imitiert NET mit falsch positivem Somatostatin-Rezeptor-PET/CT (68Ga-DOTA-TOC-PET/CT). 胰腺内继发性脾脏模拟 NET，体生长抑素受体 PET/CT 呈假阳性（68Ga-DOTA-TOC-PET/CT）。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-01 Epub Date: 2024-03-25 DOI: 10.1055/a-2166-7025

Saher Saeed, Ioannis Dimopoulos, Nehara Begum, Jan Robert Kröger

引用次数: 0

[Evaluation of risk analysis in treatment with unsealed radioactive substances in nuclear medicine]. [核医学中使用非密封放射性物质治疗的风险分析评估]。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-01 Epub Date: 2024-01-23 DOI: 10.1055/a-2237-8639

Robert Freudenberg, David Kästner, Jörg Kotzerke, Claudia Brogsitter

引用次数: 0

Red Bull PET/CT. 红牛 PET/CT。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-01 Epub Date: 2023-12-22 DOI: 10.1055/a-2195-0138

Sebastian E Serfling, Andreas Buck, Steven P Rowe, Takahiro Higuchi, Rudolf Werner

引用次数: 0

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges. 血液肿瘤学中的 CXCR4 靶向疗法：机遇与挑战。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2194-9965

Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller

{"title":"CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.","authors":"Rudolf Werner, Alexander Haug, Christian Buske, Simon Heidegger, Anna L Illert, Florian Bassermann, Peter Herhaus, Andreas Buck, Johannes Duell, Max S Topp, Sabrina Kraus, Hermann Einsele, Constantin Lapa, Markus Raderer, Georg Lenz, Stefan Habringer, Bastian von Tresckow, Ulrich Keller","doi":"10.1055/a-2194-9965","DOIUrl":"10.1055/a-2194-9965","url":null,"abstract":"<p><p>C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"57-61"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10963126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0